Responses of cultured smooth muscle cells from human nonatherosclerotic arteries and primary stenosing lesions after photoradiation: implications for photodynamic therapy of vascular stenoses.

Cultured smooth muscle cells from human nonatherosclerotic arteries and from primary stenosing lesions were labeled with dihematoporphyrinester and ether, a photosensitizing probe used mainly for the detection and photodynamic therapy of tumors. After labeling for 24 h, cells were irradiated with ultraviolet light (wavelength 365 nm, energy densities ranging from 30 to 1,200 mJ/cm2). Twenty-four hours after photoradiation, 80% of smooth muscle cells from nonatherosclerotic arteries and only 20% of smooth muscle cells from atherosclerotic plaques were viable and still adherent. Moreover, dynamic cell and cytoskeletal alterations in response to irradiation are described. The differential sensitivity of smooth muscle cells from nonatherosclerotic arteries and from atherosclerotic plaques provides evidence that a photodynamic treatment might be a valuable therapeutic approach to vascular stenosis.

Immediate and short-term benefit of multilesion coronary angioplasty: influence of degree of revascularization.

The safety and short-term therapeutic benefit of multilesion percutaneous transluminal coronary angioplasty was assessed in 135 patients, 66 of whom had a minimum of 6 months of follow-up study. Primary success, defined as successful dilation of the most critical lesion or all lesions attempted without major in-hospital complications was obtained in 117 (87%) of the 135 patients. Cardiac complications associated with the procedure were uncommon; prolonged angina occurred in 5% and myocardial infarction in 3%; emergency coronary bypass surgery was performed in 4% of the patients. There were no deaths. Complete revascularization was achieved in 46% of the 117 patients with a primary success. Of the 66 patients eligible for 6 month follow-up, 80% had an uncomplicated course and required no further procedures. Clinical improvement by at least one angina functional class was observed in 90% of the patients. Cardiac events such as the need for a second revascularization procedure were significantly more common in patients who had incomplete versus complete revascularization (35 versus 9%; p = 0.018). Repeat coronary angiography performed an average of 5 months after angioplasty revealed restenosis in 18 of 22 symptomatic patients and 3 of 9 asymptomatic patients. Restenosis occurred at the site of a single dilation in 12 patients, at two sites in 8 patients and at three sites in 1 patient. Thus, multilesion coronary angioplasty is an important therapeutic option for selected patients with multivessel disease and can be performed with relatively low risk. Improvement in angina status can be expected even in patients who have incomplete revascularization.(ABSTRACT TRUNCATED AT 250 WORDS)

Repeat coronary angioplasty.

The potential of repeat percutaneous transluminal coronary angioplasty as a mode of therapy for recurrence of stenosis after initially successful angioplasty was examined on the basis of data on all 514 patients with successful angioplasty at Emory University before April 1982. Recurrence was found in 171 (33%) of the 514 patients. Repeat angioplasty was attempted in 95 patients with a significantly higher primary success rate (97 versus 85%, p less than 0.001) and a lower complication rate (8 versus 15%, p less than 0.10) than those of initial angioplasty. Follow-up documentation was available in all 92 patients with successful repeat angioplasty. A second recurrence of stenosis was found in 26% (24 of 92). A third angioplasty was performed in seven patients; six procedures were successful and there have been no recurrences of stenosis. Repeat coronary angioplasty provides a means to treat recurrence of stenosis. It proved to be very successful and safe and yielded good long-term results. It also increased the percent of patients with documented lasting success after angioplasty from 63 to 78%.

Percutaneous transluminal coronary angioplasty in patients with prior coronary bypass surgery.

To improve symptomatic status and avoid reoperation, 122 initial and 7 repeat percutaneous transluminal coronary angioplasty procedures were performed in 116 patients with disabling angina pectoris at a mean of 26.8 months (range 2 to 132) after coronary bypass surgery. Marked angiographic improvement (greater than 30% reduction in diameter stenosis) was obtained in 107 (88%) of the 122 initial procedures and in all 7 repetitions. Mean stenosis was reduced from 78 +/- 13% (mean +/- standard deviation) to 25 +/- 13% (p less than 0.0001) and mean pressure gradient from 49 +/- 15 to 11 +/- 8 mm Hg (p less than 0.0001). Complications were: emergency surgery (three patients), Q wave infarction (one patient), myocardial infarction by enzyme criteria only (four patients) and non-occluding coronary dissection (one patient). There were no neurologic or peripheral vascular complications and no early deaths. One late death occurred 14 months after an unsuccessful but uncomplicated angioplasty procedure. At a mean follow-up of 8.3 months, 88 patients (76%) were free of angina or in improved condition. In patients followed up for at least 6 months, evidence of restenosis occurred in 9 (53%) of 17 saphenous veins, 1 (50%) of 2 proximal graft anastomoses, 4 (18%) of 22 distal graft anastomoses and 5 (14%) of 37 native coronary arteries. When coronary anatomy is suitable, percutaneous transluminal angioplasty is an attractive alternative to reoperation in symptomatic patients with prior coronary bypass surgery.

Antithrombotics in interventional cardiology: optimizing treatment and strategies.

Although the use of coronary stents has virtually abolished the threat of periprocedural obstructive dissection, subacute and acute intracoronary thrombosis and late restenosis remain a major problem with catheter-guided transluminal coronary interventions, despite significant technical advances over the last 10 years. Acute stent thrombosis emerged as a new problem with the introduction of metallic coronary prostheses (stents), which unfortunately represent an ideal stimulus for platelet deposition. Recently, dramatic progress has been achieved by focusing on the inhibition of thrombin and platelets, before and during interventional procedures. This has stimulated the search for powerful and well-tolerated antithrombotic agents-platelet inhibitors and antithrombins-so that long-term (oral) administration may become possible, if necessary. The current roles of unfractionated and low-molecular-weight heparins (LMWHs), direct thrombin inhibitors (such as hirulog and hirudin), antiplatelet agents (such as aspirin, clopidogrel, and ticlopidine) and the potential of the glycoprotein IIb/IIa receptor blockers are reviewed and put into perspective with respect to their acute and long-term clinical value.

Risk of side branch occlusion during coronary angioplasty.

To assess the risk of side branch occlusion during percutaneous transluminal coronary angioplasty (PTCA), 600 consecutive procedures were analyzed. On the basis of pre-PTCA angiograms of 557 patients in whom the balloon was actually inflated, 365 side branches in 302 patients (54% of patients) were deemed in jeopardy. A total of 122 side branches in 102 patients (18%) originated from the lesion segment itself, i.e., their take-off was narrowed (Group I, 33% of side branches at risk), whereas 243 side branches in 214 patients (38%) originated from the immediate vicinity of the stenosis in a way that they were subjected to temporary occlusion during balloon dilatation (Group II, 67% of side branches at risk). Patency of side branches was determined by consensus of 2 observers. Criteria for occlusion were disappearance, filling by collaterals, or stagnation of flow. After PTCA, 20 of 365 side branches (5%) were occluded and associated with chest pain in 5 patients, creatine kinase increase in 6, left anterior hemiblock, septal Q waves and transient atrial fibrillation in 1 and non-sustained ventricular tachycardia in 1 of the 20 patients. Exercise tolerance did not decrease. No local predilection for side branch occlusion was evident. Seventeen of 122 side branches (14%) occluded in Group I, compared with 3 of 243 (1%) in Group II (p less than 0.001). Thus, more than half of the patients who underwent PTCA had side branches at risk for iatrogenic occlusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Photodynamic therapy of vascular stenosis: results from cell culture studies on human endothelial cells.

BACKGROUND: Experimental results from human cell culture studies have shown that smooth muscle cells derived from human atherosclerotic plaques react more sensitively to photoactivated dihematoporphyrin-ester and -ether (DHE) than smooth muscle cells from human nonatherosclerotic arteries. A therapeutic concept of photodynamic therapy of vascular stenosis appears, therefore, to be promising. The prerequisite for an intravascular application is a relatively harmless application of the photosensitizing agent to the luminal lining of endothelial cells. METHODS: The effect of DHE with and without photoactivation was examined on endothelial cell cultures from human saphenous veins. The cellular uptake of DHE in relation to the serum content of the culture medium was evaluated, as well as its effect on proliferative activity, cell size, cell volume, and cellular viability. RESULTS: Intracellular uptake of DHE decreased significantly when higher serum concentrations were present in the culture medium. Incubation of cells with the photosensitizer for 9 days in the dark without light activation resulted in a significant decrease of endothelial cell proliferation only at concentrations higher than 2.5 micrograms/mL (= 2.5 mg/kg body weight for systemic application in vivo). Additional photoactivation caused no reduction of cell viability at DHE concentrations of 1 microgram/mL, but at 2.5 micrograms/mL and 5 micrograms/mL, a reduction of viable cells within 24 hours was observed in relation to the energy densities used for irradiation. CONCLUSIONS: Because smooth muscle cells from atherosclerotic plaques are, however, much more sensitive to photodynamic treatment, the concept of a photodynamic therapy of vascular stenosis may provide a good tool in the reduction of restenosis rates after recanalization of severely stenosed or even occluded arteries.

Thrombectomy with the X-SIZER catheter system in the coronary circulation: initial results from a multi-center study.

Despite the use of lytics, aggressive antiplatelet agents, stents and thrombectomy devices, intracoronary thrombus remains a challenge for interventional catheter-based techniques, mainly due to insufficient reduction of thrombus and risk of distal embolization. This study assesses the clinical safety and efficacy of the X-SIZER catheter (EndiCOR Medical, Inc., San Clemente, California), a novel device designed to remove soft atherothrombotic tissue from native coronary arteries, saphenous vein grafts and restenotic stents. The X-SIZER was used during catheter-based intervention as the initial device in patients with angiographically suspected thrombus at the target. Inclusion criteria were target lesion stenosis of > or = 70% diameter stenosis (DS) or > or = 50% DS with Thrombolysis in Myocardial Infarction (TIMI) flow reduction and a reference diameter of 3 mm. Analyses were performed for reduction of stenosis, improvement of TIMI flow grade by X-SIZER alone (X-SIZER outcome) and after final adjunct procedure (final outcome), angiographic complications (dissection, embolization, perforation), adverse clinical events during hospitalization, and device-related technical failures. Eighty-five patients (age range, 31-82 years old; 69 male) were studied. Forty-four patients with unstable angina and 31 with acute myocardial infarction (MI) were treated, including 18 saphenous vein grafts and 17 re-occluded stents. In 71/85 patients (84%), the X-SIZER reached the target lesion and was successfully activated. Technical failures were associated with tortuous anatomy or vessel caliber < 3 mm. In 60/71 patients (85%), X-SIZER success was achieved by either improving TIMI flow by at least one grade or reducing DS by at least 20% (DS pre-X-SIZER = 88 +/- 19%; DS post-X-SIZER = 60 +/- 29%) without a major adverse clinical event (i.e., death, Q-wave MI, three-fold elevation of creatine kinase, or total occlusion or perforation requiring emergency bypass surgery or emergency stenting). Creatinine kinase rise greater than 3 times baseline occurred in 2 patients without preexisting acute MI. Thrombus dislodgement occurred in 3 patients and vessel perforation without clinical sequelae occurred in 1 patient. No other major procedural complications were noted. Adjunct interventions (balloon and stent) were employed in all except two X-SIZER stand-alone cases for a final DS of 11 +/- 18%. The X-SIZER Catheter System is simple to use, safe and effective for patients with relatively large, non-tortuous target vessels. Improved catheter characteristics may expand its use to more complex anatomy.

Atrial pacing during percutaneous transluminal coronary angioplasty: results and comparison with exercise treadmill testing.

Right atrial pacing (RAP) was used to immediately assess improvement in threshold for myocardial ischemia in 23 patients undergoing angiographically successful percutaneous transluminal coronary angioplasty (PTCA). Multiple coronary lesions were present in 19 patients, and 15 had incomplete revascularization. All patients had RAP done immediately before and after completion of all dilatations, and in 13 patients pre- and post-PTCA exercise treadmill tests (ETT) were also performed. Angina occurred in 16 (70%) patients during pre-PTCA RAP, but in only 4 (17%) after PTCA (p less than .05). The electrocardiogram was positive for ischemia (horizontal or downsloping ST depression greater than or equal to 1 mm) in 18 patients (78%) during pre-PTCA RAP. However, 13 patients (57%) continued to have an ischemic response during post-PTCA RAP (not significant-NS). In 4 patients with multiple coronary lesions who had sequential pacing studies after PTCA of each lesion, the maximum degree of ST depression decreased by 1 mm or more after each dilatation in 3 patients but remained greater than or equal to 1 mm in all. In the 13 patients undergoing both RAP and ETT, angina developed in 7 during pre-PTCA RAP and in 2 after PTCA (p less than .05), compared with 8 and 3 (p less than .05) during pre- and post-PTCA ETT, respectively. Ischemic ST depression occurred in 9 patients during pre-PTCA RAP and in 6 after PTCA (NS), and in 8 and 6 (NS) during pre- and post-PTCA ETT, respectively. Concordance between the two tests was good.(ABSTRACT TRUNCATED AT 250 WORDS)

Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

BACKGROUND: Glycoprotein II b/IIIa antagonists (GPII b/IIIa-A) lower the periprocedural rate of ischemic events during high risk percutaneous coronary interventions. Their clinical impact on carotid artery stenting (CAS) remains to be determined. METHODS: We analyzed data from the Carotid Artery Stent (CAS) Registry. RESULTS: From 01/ 2000 to 06/2005 1322 CAS interventions were registered. In 94 (7.1%) procedures a GPII b/IIIa-A was used: abciximab in 8 cases (8.6%), tirofiban in 53 cases (57%) and eptifibatide in 32 cases (34.4%). The use of a GPII b/IIIa-A during CAS decreased significantly over time: from 17.6% in 2000 to 3% in 2005, p for trend <0.0001. The mean use of a GPII b/IIIa-A at the hospitals was 5.2%. More than 50% of the hospitals never used a GPII b/IIIa-A. There were no significant differences in baseline characteristics and concomitant diseases in CAS patients treated with GPII b/IIIa-A compared to those without GPII b/IIIa-A. A bilateral intervention was performed more often in patients treated with GPII b/IIIa-A (2.1 vs 0.2%, p = 0.04), a thrombus was more often visible (27 vs 12.4%, p <0.001) and an ulcer more frequently diagnosed (50 vs 37.5%, p = 0.03). There was no significant difference in the combined death or stroke rate between the two groups (5.3 vs 3.0%, p = 0.22, OR = 1.81, 95% CI: 0.69-4.72), which was confirmed by logistic regression analysis after adjusting for possible confounders (OR = 1.67, 95% CI: 0.62-4.46, p = 0.31). CONCLUSIONS: Our data neither demonstrate a significant benefit nor a significant risk with the use of GPIIb/IIIa-A during CAS. However, only an adequately sized randomized controlled clinical trial could establish the real value of GPII b/IIIa-A during CAS. Until then, considering the potential increase in cerebral hemorrhage, we should not use GPII b/ IIIa-A routinely during CAS.

Carotid artery stenting in clinical practice results from the Carotid Artery Stenting (CAS)-registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK).

BACKGROUND: Carotid artery stenting (CAS) for symptomatic and asymptomatic carotid stenosis seems to be on the doorstep of more widespread use. However, its feasibility and safety in clinical practice at a broad spectrum of hospitals needs to be determined. METHODS: We analyzed data of the prospective multi-centre Carotid Artery Stenting (CAS) Registry of the German Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). RESULTS: From 7/1996 to 5/2004 1888 patients from 28 hospitals were included in the CAS Registry. The median hospital stay from CAS until hospital discharge was 3 days (quartiles: 2-6 days). Median patients age was 70 years (quartiles: 64-76 years) with 72.1% males. CAS for symptomatic stenosis was performed in 55% of cases. Patients treated with CAS suffered from coronary artery disease in 66.5%, had arterial hypertension in 91.7%, hyperlipidemia in 86.3% and 34.2% were diabetics. The intended CAS procedure was completed in 98.1% of cases. A stent was implanted in 97.3% of completed cases. The median intervention time was 43 min (quartiles: 30-60 min). During the hospital stay death rate was 0.3% (5/1888) and the rate of ipsilateral stroke 3.2% (58/1840). A contralateral ischemic event occurred in 1.4% (26/ 1840) of patients. The combined rate of all death or strokes was 3.8% (70/1841). Between 1996 and 2004 there was a steady increase in the use of protection devices during CAS (0% in 1996 and 97.9% in 2004; p for trend <0.0001). There was also an increase in the proportion of patients treated for asymptomatic stenoses (p for trend <0.0001). We observed a decrease of the combined endpoint of death or stroke from 6.3% in 1996 to 1.9% in 2004 (p for trend=0.021). CONCLUSION: The multi-centre ALKK CAS Registry data confirm the feasibility and shot-term safety of CAS even in daily clinical practice. There was a rapid penetration of the use of embolic protection devices, an increase in treatment of asymptomatic carotid stenoses and a decrease in acute complication rates from 1996 to 2004.

Carotid stenting: which stent for which lesion?

Dedicated catheter and stent systems for use in the carotid circulation have only been developed recently. Almost exclusively, self-expandable metallic stents are being used. Longitudinal flexibility, contourability of the luminal configuration, sufficient radial resistive force, narrow meshwork for sealing of the diseased vessel wall, low profile of the constraint stent, and compatibility of the devices with routine angioplasty techniques are the premier requirements. Most of the current experience is based on the longitudinal wire mesh design (Carotid Wallstent). The narrow meshwork has excellent sealing capacity but the inherent (yet manageable) problem of foreshortening with expansion needs attention. The segmented ring designs of the more recent Nitinol stents permit more precise positioning and contouring of the luminal surface, yet their capacity to seal a complex or thrombotic lesion and their clinical safety needs further evaluation. As more distinct features of dedicated carotid stents are being developed and as their differential importance gets recognized, a more meaningful and individual stent selection for the carotid anatomy may further improve clinical outcome.

Late progression of an asymptomatic intimal tear to occlusive coronary artery dissection following angioplasty.

Symptomatic coronary artery dissection is a recognized complication of coronary angioplasty that is usually associated with immediate adverse consequences. In contrast, the asymptomatic angiographic finding of an "intimal tear" following otherwise successful angioplasty has been considered clinically unimportant. A case is reported of a primarily successful coronary angioplasty with intimal tear that progressed to occlusive coronary artery dissection requiring coronary bypass surgery at 4 weeks postangioplasty. This case demonstrates that an asymptomatic intimal tear following successful coronary angioplasty is not always an innocuous angiographic finding.

Experience with a technique for coronary angioplasty of bifurcational lesions.

To decrease the risk of iatrogenic side branch occlusion during coronary angioplasty of bifurcational lesions, we evaluated a technique in which two over-the-wire dilatation systems are positioned within the stenosed coronary artery and the side branch in jeopardy. The technique was used in eight patients undergoing angioplasty for a lesion in the left anterior descending or circumflex artery located near a large side branch. Successful dilatation of the major vessel lesion was achieved in all eight patients, and dilatation within the side branch was successful in all three patients whose lesion involved the side branch ostium. In one patient, dilatation within the major vessel led to partial closure of the side branch and the prepositioned guide wire facilitated prompt dilatation of the iatrogenic closure. There were no complications associated with use of the additional dilatation system. The technique appears to provide an efficacious method to perform safe coronary angioplasty in selected patients with bifurcational lesions.

Differential effect of Photofrin II on growth of human smooth muscle cells from nonatherosclerotic arteries and atheromatous plaques in vitro.

The effect of dihematoporphyrin-ester or -ether (DHE), a photosensitizing porphyrin with different amounts of aggregates, on the growth of cultured smooth muscle cells obtained from nonatherosclerotic arteries and from atheromatous plaques (primary stenosing and restenosing lesions) was examined without photoactivation of the drug. Clinically relevant DHE concentrations ranging from 0.1 to 25 micrograms/ml were used. In all proliferation studies with cells of second and third passage (approximately 10 cumulative population doublings in vitro), the growth rates decreased in a dose-dependent manner. Smooth muscle cells from atherosclerotic lesions were significantly more sensitive than smooth muscle cells from normal arteries. Cells derived from restenosing lesions retained their increased sensitivity even after eight passages in culture (approximately 20 cumulative population doublings). Cell size measurements showed that the decreased proliferative activity mainly occurred in smooth muscle cell subpopulations consisting of small cells. A cytotoxic effect of DHE was observed at concentrations above 5 micrograms/ml, causing cytoplasmic protrusions, vacuoles, and even complete cell lysis. At a DHE concentration of 5 micrograms/ml, the number of viable cells was 73% +/- 14% (means +/- SD) for smooth muscle cells from nonatherosclerotic arterial media and only 38% +/- 11% (means +/- SD) for smooth muscle cells from atherosclerotic plaques. In all experiments, no significant difference in response to DHE treatment was observed between cells from primary stenosing and restenosing lesions, suggesting a specific mechanism for plaque-derived cells causing an increased sensitivity in comparison to smooth muscle cells from nonatherosclerotic arteries. The pronounced sensitivity of plaque cells against DHE treatment suggests that this drug--even without photoactivation--is potentially valuable in vivo as a therapeutic approach to vascular stenoses.

Partial malposition of PFO closure device: indication for elective surgical removal? Discussion of indications, procedural and anatomical aspects.

Partial malposition of a PFO closure device occurred, probably due to a right atrial ligamentous structure. Despite absence of residual shunt and uneventful postprocedural course, elective surgical removal was performed. Indications, procedural and anatomical aspects are discussed.

[Effect of dihematoporphyrin derivatives on cultivated human smooth muscle cells from normal and atherosclerotic vascular segments-- Overview of results and implications for photodynamic therapy]. / Wirkung von Dihämatoporphyrin-Derivaten auf kultivierte glatte Muskelzellen des Menschen aus normalen und atherosklerotisch veränderten Gefässsegmenten--Ubersicht über bisherige Ergebnisse und Implikationen für eine photodynamische Therapie.

It is little known that photosensitizing porphyrins can be used not only for the localization and photodynamic therapy of tumors, but that they also accumulate in atherosclerotic plaques. This observation might be of interest for the detection and therapy of vascular stenoses. The present study examines whether dihematoporphyrin-ester and -ether, at clinically relevant concentrations, selectively influence cultured smooth muscle cells from human atherosclerotic plaques (primary stenoses and secondary stenoses) in comparison to smooth muscle cells obtained from non-atherosclerotic arteries. The results demonstrate that the drug accumulated to a greater extent in plaque-derived cells than in smooth muscle cells from normal arteries. Even without photoactivation, dihematoporphyrin-ester and -ether significantly decreased the proliferative activity of cells from atherosclerotic plaques. Light exposure of porphyrin-labeled cells resulted in a more pronounced sensitivity of plaque cells when compared with smooth muscle cells from non-atherosclerotic arterial wall. A comparison of the proliferative activity of cells before and after photodynamic reaction demonstrated that this activity was unaltered in surviving smooth muscle cells from non-atherosclerotic arteries, whereas surviving plaque-derived cells exhibited a significantly decreased or even non-proliferative activity. From the in vitro studies, a porphyrin concentration of 1-5 micrograms/ml (= 1-5 mg/kg body weight in vivo after systemic application) seems to be the most suitable dosage. In addition, morphological alterations of the cells caused by photodynamic reaction were documented.(ABSTRACT TRUNCATED AT 250 WORDS)

Coronary dissection and total coronary occlusion associated with percutaneous transluminal coronary angioplasty: significance of initial angiographic morphology of coronary stenoses.

Coronary dissection and total coronary occlusion leading to emergency coronary surgery are the most frequent complications of percutaneous transluminal coronary angioplasty (PTCA) and their occurrence usually is unpredictable. To identify angiographic characteristics of coronary stenoses that may affect the incidence of these complications, the diagnostic pre-PTCA coronary angiograms of 38 consecutive patients (group I) undergoing emergency coronary surgery for dissection or occlusion were reviewed and compared with the angiograms of a random sample of 38 patients (stratified for left anterior descending and right coronary arteries) from a group of 1151 who did not need emergency coronary surgery (group II). Stenosis morphology before angioplasty was considered "complicated" if at least one of the following criteria was present: irregular borders, intraluminal lucency, and localization of stenosis in curve or at bifurcation. Baseline characteristics, maximum inflation pressures, types of balloon catheters used, and routinely registered angiographic stenosis properties (severity, length, eccentricity, and calcification) were similar in both groups. Irregular borders before PTCA were present in 22 of 38 patients in group I vs 10 of 38 in group II (p less than .05), intraluminal lucency in 22 of 38 vs nine of 38 (p less than .05), localization in curve in 27 of 38 pts vs 16 of 38 (p less than .05), and localization at bifurcation in 11 of 38 vs 15 of 38 (NS). Complicated angiographic morphology of coronary stenosis may represent a risk factor for dissection or occlusion. Therefore, although the predictive value of these findings is low, detailed evaluation of angiographic morphology of coronary stenoses may improve patient selection and reduce complication rates of PTCA.

[Positive inotropic effects of doxaminol in congestive heart failure]. / Positiv-inotrope Akuteffekte von Doxaminol bei Herzinsuffizienz.

The hemodynamic effects of doxaminol, a new, orally applicable beta-agonist, chemically dissimilar to catecholamines, were studied in comparison to those of dobutamine by means of thermodilution. After single-dose application of doxaminol in cases of congestive heart failure, cardiac output and stroke volume increased, heart rate increased slightly, pulmonary and systemic arterial pressure remained constant, and peripheral vascular resistance decreased. No arrhythmias appeared, but one patient suffered an attack of angina.